Sagida Bibi
Impact in
- Infectious Diseases top 0.05%
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- SARS-CoV-2 detection and testing
- Viral gastroenteritis research and epidemiology
- Health top 0.1%
- Vaccine Coverage and Hesitancy
Papers in
-
- SARS-CoV-2 and COVID-19 Research 46
- COVID-19 Clinical Research Studies 16
- SARS-CoV-2 detection and testing 8
- Viral Infections and Outbreaks Research 4
-
- Bacterial Infections and Vaccines 7
- Co-authors
- Yvonne Perrie (2 shared papers)Eric Lattmann (2 shared papers)Afzal-Ur-Rahman Mohammed (2 shared papers)Malou Henriksen‐Lacey (1 shared paper)Jitinder S. Wilkhu (1 shared paper)Dennis Christensen (1 shared paper)Sarah E. McNeil (1 shared paper)Randip Kaur (1 shared paper)
- Journals
- Nature Communications (8 papers)Cell (7 papers)The Lancet (7 papers)Nature Medicine (5 papers)Wellcome Open Research (3 papers)
- Partner nations
- United KingdomNetherlandsUnited States
In The Last Decade
Sagida Bibi
63 papers receiving 14.2k citations
Sagida Bibi's Hit Papers
Peers
Comparison fields: 5 of 160
- Infectious Diseases 11.3k
- Health 2.1k
- Modeling and Simulation 1.1k
- Animal Science and Zoology 1.2k
- Immunology 1.4k
Countries citing papers authored by Sagida Bibi
This map shows the geographic impact of Sagida Bibi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sagida Bibi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sagida Bibi more than expected).
Fields of papers citing papers by Sagida Bibi
This network shows the impact of papers produced by Sagida Bibi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sagida Bibi. The network helps show where Sagida Bibi may publish in the future.
Co-authors
The 25 scholars most cited alongside Sagida Bibi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 68 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Hit paper breakdown → | 2020 | 3621 |
| 2 | Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial Hit paper breakdown → | 2020 | 1899 |
| 3 | Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials Hit paper breakdown → | 2021 | 867 |
| 4 | Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection Hit paper breakdown → | 2021 | 865 |
| 5 | Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera Hit paper breakdown → | 2021 | 755 |
| 6 | Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum Hit paper breakdown → | 2021 | 558 |
| 7 | Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum Hit paper breakdown → | 2022 | 547 |
| 8 | Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial Hit paper breakdown → | 2020 | 505 |
| 9 | 2020 | 469 | |
| 10 | Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial Hit paper breakdown → | 2021 | 465 |
| 11 | Antibody evasion by the P.1 strain of SARS-CoV-2 Hit paper breakdown → | 2021 | 452 |
| 12 | Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera Hit paper breakdown → | 2021 | 353 |
| 13 | Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study Hit paper breakdown → | 2022 | 335 |
| 14 | 2020 | 281 | |
| 15 | 2020 | 251 | |
| 16 | A blood atlas of COVID-19 defines hallmarks of disease severity and specificity Hit paper breakdown → | 2022 | 209 |
| 17 | 2021 | 188 | |
| 18 | 2021 | 182 | |
| 19 | 2020 | 171 | |
| 20 | 2022 | 134 |
About Sagida Bibi
Sagida Bibi is a scholar working on Infectious Diseases, Microbiology, Animal Science and Zoology, Immunology and Epidemiology, having authored 68 papers that have together received 14.5k indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (46 papers), COVID-19 Clinical Research Studies (16 papers), SARS-CoV-2 detection and testing (8 papers), Animal Virus Infections Studies (7 papers), Bacterial Infections and Vaccines (7 papers), Immunotherapy and Immune Responses (6 papers), RNA Interference and Gene Delivery (4 papers) and Viral Infections and Outbreaks Research (4 papers). The work is most often cited by research in Infectious Diseases (11.3k citations), Health (2.1k citations), Modeling and Simulation (1.1k citations), Animal Science and Zoology (1.2k citations) and Immunology (1.4k citations). Sagida Bibi has collaborated with scholars based in United Kingdom, Netherlands and United States. Frequent co-authors include Yvonne Perrie, Eric Lattmann, Afzal-Ur-Rahman Mohammed, Malou Henriksen‐Lacey, Jitinder S. Wilkhu, Dennis Christensen, Sarah E. McNeil, Randip Kaur, Andrew John Pollard and Teresa Lambe. Their work appears in journals such as Nature Communications, Cell, The Lancet, Nature Medicine and Wellcome Open Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.